会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • INDUSTRIAL METHOD FOR THE SYNTHESIS OF 17-ACETOXY-11ß-[4-(DIMETHYLAMINO)-PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIEN-3,20-DIONE AND THE KEY INTERMEDIATES OF THE PROCESS
    • 合成17-乙酰基-11β-[4-(二甲基氨基)苯基] -2-甲氧基-19-壬基-4,9-二烯-3,20-二酮的工业方法及其工艺的主要中间体
    • WO2009001148A3
    • 2009-03-19
    • PCT/HU2008000073
    • 2008-06-19
    • RICHTER GEDEON NYRTBODI JOZSEFVISKY GYOERGYSZELES JANOSMAHO SANDORSANTA CSABACSOERGEI JANOSTUBA ZOLTANTERDY LASZLOMOLNAR CSABAARANYI ANTALHORVATH ZOLTANBALOGH GABOR
    • BODI JOZSEFVISKY GYOERGYSZELES JANOSMAHO SANDORSANTA CSABACSOERGEI JANOSTUBA ZOLTANTERDY LASZLOMOLNAR CSABAARANYI ANTALHORVATH ZOLTANBALOGH GABOR
    • C07J21/00C07J41/00C07J51/00
    • C07J41/0083C07J21/006C07J41/0094C07J51/00Y02P20/55
    • The present invention relates to a process for the synthesis of the known 17-acetoxy-11-ß-[4-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-etandiyl-bis(oxy)]-oestr-5(10),9(l l)-dien-17-one of formula (II). Compound CDB-4124 belongs to the group of anti-hormones. The process according to the invention is the following: i) formation of an epoxide on the double bond in position 5(10) of 3,3-[l,2-ethandiyl- bis(oxy)]-oestr-5(10),9(l l)-dien-17-one of formula (II) with hydrogen peroxide; ii) addition of hydrogen cyanide formed in situ on position 17 of the obtained 5,10a- epoxy-3,3-[l,2-ethandiyl-bis(oxy)]-5a-oestr-9(l l)-en-17-one of formula (III); iii) silylation of the hydroxyl group in position 17 of the formed 5,10a-epoxy-3,3-[l,2- ethandiyl-bis(oxy)]-17a-hydroxy-5a-oestr-9(l l)-en-17ß-carbonitrile of formula (IV) with trimethyl chlorosilane; iv) reacting the obtained 5,10a-epoxy-3,3-[l,2-ethandiyl-bis(oxy)]-17-[trimethyl-silyl-oxy]-5a-oestr-9(l l)-en-17ß-carbonitrile of formula (V) with 4-(dimethylamino)-phenyl magnesium bromide Grignard reagent in the presence of CuCl (Teutsch reaction); v) silylation of the hydroxyl group in position 5 of the formed l lß-[4-(dimethyl-amino)-phenyl] -3,3 - [1,2-ethandiyl-bis(oxy)] -5 -hydroxy- 17a- [trimethylsilyl-(oxy)] -5 a-oestr-9-en-17ß-carbonitrile of formula (VI) with trimethyl chlorosilane; vi) reacting the obtained llß-[4-(dimethylamino)-phenyl]-3,3-[l,2-ethandiyl-bis(oxy)]-5,17a-bis-[trimethyl-silyl-(oxy)]-5a-oestr-9-en-17ß-carbonitrile of formula (VII) with diisobutyl aluminum hydride and after addition of acid to the reaction mixture; vii) methoxy-methylation of the obtained l lß-[4-(dimethylamino)-phenyl]-3,3-[1,2-ethandiyl-bis(oxy)]-5, 17a-bis-[trimethyl-silyl-(oxy)]-5a-oestr-9-en-17ß-carbaldehide of formula (VIII) with methoxy-methyl Grignard reagent formed in situ, while hydrolyzing the trimethylsilyl protective groups; viii) oxidation of the hydroxyl group in position 20 of the obtained 17,20?-dihydroxy-11ß-[4-(dimemylarnino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3-one of formula (IX) with dicyclohexyl carbodiimide in the presence of dimethyl sulfoxide and a strong organic acid (Swern oxidation), and in given case after purification by chromatography; ix) acetylation of the hydroxyl group in position 17 of the obtained 11ß-[4-(dimethylamino)-phenyl] -17-hydroxy-21-methoxy-19-norpregna-4,9-dien-3,20-dione of formula (X) with acetic anhydride in the presence of perchloric acid, and in given case the obtained 7-acetoxy-11ß-[4-(dimethylamino)-phenyl)]-21-methoxy-19-norpregna-4,9-dien-3,20-dione of formula (I) is purified by chromatography. The invention also relates to the new intermediates of formula (VII) and (VIII).
    • 本发明涉及合成已知的17-乙酰氧基-11-β-[4-(二甲基氨基) - 苯基] -2-甲氧基-19-去甲基-4,9-二烯-3,20-二酮 (10),9(11) - 二酮-17-(式(I)的化合物(CDB-4124) II)。 化合物CDB-4124属于抗激素类。 根据本发明的方法如下:i)在3,3- [1,2-乙二基 - 双(氧基)] - 甲酯-5(10)的5(10)位的双键上形成环氧化物, ,(II)的9(II) - 二烯-17-酮与过氧化氢反应; ii)在获得的5,10a-环氧-3,3- [1,2-乙二基 - 双(氧基)]-5α-异(9)-en-17的位置17上原位形成的氰化氢的加入 - 一个式(III)的化合物; iii)形成的5,10a-环氧-3,3- [1,2-乙二基 - 双(氧基)]-17α-羟基-5a-甲酯-9(11)-en的17位羟基的甲硅烷基化 (IV)的-17β-腈与三甲基氯硅烷反应; iv)使得到的5,10a-环氧-3,3- [1,2-乙二基 - 双(氧基)] - 17- [三甲基 - 甲硅烷氧基] -5a-甲酯-9(II)-en-17β (V)与4-(二甲基氨基) - 苯基溴化镁Grignard试剂在CuCl存在下的反应(Teutsch反应); v)形成的11β-[4-(二甲基 - 氨基) - 苯基] -3,3 - [1,2-乙二基 - 双(氧基)] -5-羟基-17α的位置5的羟基的甲硅烷基化 - (三甲基甲硅烷基 - (氧基)]-5α-甲基-9-烯-17β-甲腈与三氯甲硅烷; vi)使所得的11β-[4-(二甲基氨基) - 苯基] -3,3- [1,2-乙二基 - 双(氧基)] -5,17a-双 - [三甲基 - 甲硅烷基 - (氧基) (Ⅶ)的5-甲基-9-烯-17β-腈与二异丁基氢化铝反应,并向反应混合物中加入酸; vii)所得的11β-[4-(二甲基氨基) - 苯基] -3,3- [1,2-乙二基 - 双(氧基)] -5,17a-双 - [三甲基甲硅烷基 - ( 氧基)]-5α-甲基-9-烯-17β-al底物与甲氧基甲基格氏试剂原位形成,同时水解三甲基甲硅烷基保护基; viii)所获得的17,20β-二羟基-11β-[4-(二甲基氨基)苯基] -21-甲氧基-19-去甲基-4,9-二烯-3-酮的20位羟基氧化 式(Ⅸ)与二环己基碳二亚胺在二甲基亚砜和强有机酸(Swern氧化)存在下反应,在给定的情况下通过色谱纯化; ix)得到的17β-[4-(二甲基氨基) - 苯基] -17-羟基-21-甲氧基-19-去甲基-4,9-二烯-3,20-二酮的17位羟基乙酰化为式 (X)与高氯酸存在下的乙酸酐反应,在给定情况下得到的7-乙酰氧基-11β-[4-(二甲基氨基) - 苯基)] - 21-甲氧基-19-去甲基-4,9-二烯 - (I)的3,20-二酮通过色谱法纯化。 本发明还涉及式(VII)和(VIII)的新中间体。
    • 2. 发明申请
    • HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
    • 高纯度17a-氰基甲基-17β-羟基-ESTRA-4,9-二烯-3-酮及其合成方法
    • WO2007066158A2
    • 2007-06-14
    • PCT/HU2006/000091
    • 2006-10-11
    • RICHTER GEDEON VEGYÉSZETI GYÁR RT.DANCSI, LajosnéMAHÓ, SándorARANYI, AntalHORVÁTH, János
    • DANCSI, LajosnéMAHÓ, SándorARANYI, AntalHORVÁTH, János
    • C07J41/00
    • C07J41/0094
    • The invention relates to a new process for the synthesis of high purity 17α- cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents. According to our invention the dienogest of formula (I) is synthesized the following way: i) 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) is reacted.with aluminum isopropylate in the presence of cyclohexanone in an inert organic solvent under heating; ii) the so obtained 3-methoxy-estra-2,5(10)-diene-17-one of formula (IV) is reacted with cyanomethyl lithium at a temperature between 0 and -30°C; iii) the obtained 3-methoxy-17α-cyanomethyl-17β-hydroxy-estra-2,5(10)-diene of formula (III) is reacted with a strong organic acid in tetrahydrofuran solution; iv) the obtained 17α-cyanomethyl-17β-hydroxy-estr-5(10)-ene-3-one of formula (II) is reacted with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 60°C, then the obtained crude dienogest of formula (I) is purified by recrystallization and preparative HPLC.
    • 本发明涉及一种从3-甲氧基-17-羟基(Ⅰ)合成式(I)的高纯度17a-氰基甲基-17β-羟基 - 雌-4,9-二烯-3-酮(另外在二烯酸酯)上合成的新方法。 式(V)的-estra-2,5(10) - 二烯。 本发明还涉及高纯度的17α-氰基甲基-17β-羟基 - 雌-4,9-二烯-3-酮和含有它作为活性成分的药物组合物。 根据本发明的药物组合物含有杂质总量小于0.1%的高纯度的配方(D),而4-溴 - 二烯酸的用量为检测限(0.02%)作为有效成分 或至少一种活性成分和辅助材料,其通常用于实践中,例如载体,赋形剂或稀释剂。 根据我们的发明,通过以下方式合成式(I)的地那诺酯:i)式(Ⅴ)的3-甲氧基-17-羟基 - 雌-2,5(10) - 二烯与异丙醇铝在 加热下在惰性有机溶剂中存在环己酮; ii)如此获得的式(IV)的3-甲氧基 - 雌-2,5(10) - 二烯-17-与氰甲基锂在0和-30℃之间的温度下反应; iii)得到的式(III)的3-甲氧基-17α-氰基甲基-17β-羟基 - 雌-2,5(10) - 二烯与强有机酸在四氢呋喃溶液中反应; iv)将得到的式(II)的17α-氰基甲基-17β-羟基 - 雌-5(10) - 烯-3-酮与1-1.5当量吡啶三溴化物在吡啶溶液中在0至60℃的温度下反应 然后通过重结晶和制备型HPLC纯化得到的式(I)粗制二烯酸。
    • 4. 发明申请
    • INDUSTRIAL METHOD FOR THE SYNTHESIS OF 17-ACETOXY-11β-[4-(DIMETHYLAMINO)-PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIEN-3,20-DIONE AND THE KEY INTERMEDIATES OF THE PROCESS
    • 合成17-乙酰基-11β-[4-(二甲基氨基)苯基] -2-甲氧基-19-壬基-4,9-二烯-3,20-二酮的工业方法及其工艺的主要中间体
    • WO2009001148A2
    • 2008-12-31
    • PCT/HU2008/000073
    • 2008-06-19
    • RICHTER GEDEON NYRT.BÓDI, JózsefVISKY, GyörgySZÉLES, JánosMAHÓ, SándorSÁNTA, CsabaCSÖRGEI, JánosTUBA, ZoltánTERDY, LászlóMOLNÁR, CsabaARANYI, AntalHORVÁTH, ZoltánBALOGH, Gábor
    • BÓDI, JózsefVISKY, GyörgySZÉLES, JánosMAHÓ, SándorSÁNTA, CsabaCSÖRGEI, JánosTUBA, ZoltánTERDY, LászlóMOLNÁR, CsabaARANYI, AntalHORVÁTH, ZoltánBALOGH, Gábor
    • C07J41/0083C07J21/006C07J41/0094C07J51/00Y02P20/55
    • The present invention relates to a process for the synthesis of the known 17-acetoxy-11-β-[4-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-etandiyl-bis(oxy)]-oestr-5(10),9(l l)-dien-17-one of formula (II). Compound CDB-4124 belongs to the group of anti-hormones. The process according to the invention is the following: i) formation of an epoxide on the double bond in position 5(10) of 3,3-[l,2-ethandiyl- bis(oxy)]-oestr-5(10),9(l l)-dien-17-one of formula (II) with hydrogen peroxide; ii) addition of hydrogen cyanide formed in situ on position 17 of the obtained 5,10α- epoxy-3,3-[l,2-ethandiyl-bis(oxy)]-5α-oestr-9(l l)-en-17-one of formula (III); iii) silylation of the hydroxyl group in position 17 of the formed 5,10α-epoxy-3,3-[l,2- ethandiyl-bis(oxy)]-17α-hydroxy-5α-oestr-9(l l)-en-17β-carbonitrile of formula (IV) with trimethyl chlorosilane; iv) reacting the obtained 5,10α-epoxy-3,3-[l,2-ethandiyl-bis(oxy)]-17-[trimethyl-silyl-oxy]-5α-oestr-9(l l)-en-17β-carbonitrile of formula (V) with 4-(dimethylamino)-phenyl magnesium bromide Grignard reagent in the presence of CuCl (Teutsch reaction); v) silylation of the hydroxyl group in position 5 of the formed l lβ-[4-(dimethyl-amino)-phenyl] -3,3 - [1,2-ethandiyl-bis(oxy)] -5 -hydroxy- 17α- [trimethylsilyl-(oxy)] -5 α-oestr-9-en-17β-carbonitrile of formula (VI) with trimethyl chlorosilane; vi) reacting the obtained llβ-[4-(dimethylamino)-phenyl]-3,3-[l,2-ethandiyl-bis(oxy)]-5,17α-bis-[trimethyl-silyl-(oxy)]-5α-oestr-9-en-17β-carbonitrile of formula (VII) with diisobutyl aluminum hydride and after addition of acid to the reaction mixture; vii) methoxy-methylation of the obtained l lβ-[4-(dimethylamino)-phenyl]-3,3-[1,2-ethandiyl-bis(oxy)]-5, 17α-bis-[trimethyl-silyl-(oxy)]-5α-oestr-9-en-17β-carbaldehide of formula (VIII) with methoxy-methyl Grignard reagent formed in situ, while hydrolyzing the trimethylsilyl protective groups; viii) oxidation of the hydroxyl group in position 20 of the obtained 17,20ξ-dihydroxy-11β-[4-(dimemylarnino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3-one of formula (IX) with dicyclohexyl carbodiimide in the presence of dimethyl sulfoxide and a strong organic acid (Swern oxidation), and in given case after purification by chromatography; ix) acetylation of the hydroxyl group in position 17 of the obtained 11β-[4-(dimethylamino)-phenyl] -17-hydroxy-21-methoxy-19-norpregna-4,9-dien-3,20-dione of formula (X) with acetic anhydride in the presence of perchloric acid, and in given case the obtained 7-acetoxy-11β-[4-(dimethylamino)-phenyl)]-21-methoxy-19-norpregna-4,9-dien-3,20-dione of formula (I) is purified by chromatography. The invention also relates to the new intermediates of formula (VII) and (VIII).
    • 本发明涉及合成已知的17-乙酰氧基-11-β-[4-(二甲基氨基) - 苯基] -2-甲氧基-19-去甲基-4,9-二烯-3,20-二酮 (10),9(11) - 二酮-17-(式(I)的化合物(CDB-4124) II)。 化合物CDB-4124属于抗激素类。 根据本发明的方法如下:i)在3,3- [1,2-乙二基 - 双(氧基)] - 甲酯-5(10)的5(10)位的双键上形成环氧化物, ,(II)的9(II) - 二烯-17-酮与过氧化氢反应; ii)在获得的5,10a-环氧-3,3- [1,2-乙二基 - 双(氧基)]-5α-异(9)-en-17的位置17上原位形成的氰化氢的加入 - 一个式(III)的化合物; iii)形成的5,10a-环氧-3,3- [1,2-乙二基 - 双(氧基)]-17α-羟基-5a-甲酯-9(11)-en的17位羟基的甲硅烷基化 (IV)的-17β-腈与三甲基氯硅烷反应; iv)使得到的5,10a-环氧-3,3- [1,2-乙二基 - 双(氧基)] - 17- [三甲基 - 甲硅烷氧基] -5a-甲酯-9(II)-en-17β (V)与4-(二甲基氨基) - 苯基溴化镁Grignard试剂在CuCl存在下的反应(Teutsch反应); v)形成的11β-[4-(二甲基 - 氨基) - 苯基] -3,3 - [1,2-乙二基 - 双(氧基)] -5-羟基-17α的位置5的羟基的甲硅烷基化 - (三甲基甲硅烷基 - (氧基)]-5α-甲基-9-烯-17β-甲腈与三氯甲硅烷; vi)使所得的11β-[4-(二甲基氨基) - 苯基] -3,3- [1,2-乙二基 - 双(氧基)] -5,17a-双 - [三甲基 - 甲硅烷基 - (氧基) (Ⅶ)的5-甲基-9-烯-17β-腈与二异丁基氢化铝反应,并向反应混合物中加入酸; vii)所得的11β-[4-(二甲基氨基) - 苯基] -3,3- [1,2-乙二基 - 双(氧基)] -5,17a-双 - [三甲基甲硅烷基 - ( 氧基)]-5α-甲基-9-烯-17β-al底物与甲氧基甲基格氏试剂原位形成,同时水解三甲基甲硅烷基保护基; viii)所获得的17,20β-二羟基-11β-[4-(二甲基氨基)苯基] -21-甲氧基-19-去甲基-4,9-二烯-3-酮的20位羟基氧化 式(Ⅸ)与二环己基碳二亚胺在二甲基亚砜和强有机酸(Swern氧化)存在下反应,在给定的情况下通过色谱纯化; ix)得到的17β-[4-(二甲基氨基) - 苯基] -17-羟基-21-甲氧基-19-去甲基-4,9-二烯-3,20-二酮的17位羟基乙酰化为式 (X)与高氯酸存在下的乙酸酐反应,在给定情况下得到的7-乙酰氧基-11β-[4-(二甲基氨基) - 苯基)] - 21-甲氧基-19-去甲基-4,9-二烯 - (I)的3,20-二酮通过色谱法纯化。 本发明还涉及式(VII)和(VIII)的新中间体。